rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CVKD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cadrenal Therapeutics initiates strategic review process
      Oct 7Investing.comCVKD
      Cadrenal Therapeutics shareholders approve equity plan amendment and warrant issuance
      Sep 29Investing.comCVKD
      Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
      Sep 21Yahoo FinanceCVKD
      Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

      PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in the 28th Annual H.C. Wainwright Global Investment Conference, September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded presentation from the Company will be available on demand

      Sep 3Yahoo FinanceCVKD
      Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

      FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions,

      Aug 31Yahoo FinanceCVKD
      CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise

      By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Launches Strategic Partnering Process for Cardiac Acute Critical Care Franchise Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) has launched a structured strategic partnering process for its Cardiac Acute Critical Care Franchise that is centered on three commercial pillars. At this time, the company will not be

      Aug 31Yahoo FinanceCVKD

      This is the newest page. Registered accounts read further back.